Drug
Ux016
Ux016: highest development phase Phase 1/2, developed by Ultragenyx Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| UX016 NCT07511556 | Phase 1/2 | GNE Myopathy |
Latest
No recent events.
Follow Ux016 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.